Vairavan Latha
SVP Chief Financial Officer
Vairavan Latha has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: May 13, 2026.
On the most recent filing, Vairavan Latha is listed as SVP Chief Financial Officer at Arcutis Biotherapeutics, Inc. Inside the rolling window, Vairavan Latha reported no open-market purchases and 4 open-market sales totaling $146K in ARQT. The largest disclosed transaction in the window is a sale of 2,853 ARQT shares on Mar 2, 2026, worth $72K.
Companies traded
Other insiders at ARQT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$146K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Nov 3, 2025 | ARQT | Sale | $2K |
Frequently asked questions
How many SEC Form 4 filings has Vairavan Latha made?
Vairavan Latha has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Vairavan Latha trade?
Vairavan Latha has filed SEC Form 4 disclosures for 1 company, including ARQT.
When was Vairavan Latha's most recent SEC Form 4 filing?
Vairavan Latha's most recent SEC Form 4 filing on Tracefour is dated May 13, 2026.
What is Vairavan Latha's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Vairavan Latha is listed as SVP Chief Financial Officer.
What is Vairavan Latha's total buy and sell value in the current window?
Inside the rolling retention window, Vairavan Latha bought $0 and sold $146K based on SEC Form 4 filings.
What was Vairavan Latha's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,853 ARQT shares on 2026-03-02, worth $72K, per SEC Form 4 filings.